The HMG box containing protein UBF binds to the promoter of vertebrate ribosomal repeats and is required for their transcription by RNA polymerase I in vitro. UBF can also bind in vitro to a variety of sequences found across the intergenic spacer in Xenopus and mammalian ribosomal DNA (rDNA) repeats. The high abundance of UBF, its colocalization with rDNA in vivo, and its DNA binding characteristics, suggest that it plays a more generalized structural role over the rDNA repeat. Until now this view has not been supported by any in vivo data. Here, we utilize chromatin immunoprecipitation from a highly enriched nucleolar chromatin fraction to show for the first time that UBF binding in vivo is not restricted to known regulatory sequences but extends across the entire intergenic spacer and transcribed region of Xenopus, human, and mouse rDNA repeats. These results are consistent with a structural role for UBF at active nucleolar organizer regions in addition to its recognized role in stable transcription complex formation at the promoter.
Blocking the function of Stat (signal transducer and activator of transcription) proteins, which are critical for antiviral responses, has evolved as a common mechanism for pathogen immune evasion. The poxvirus-encoded phosphatase H1 is critical for viral replication, and may play an additional role in the evasion of host defense by dephosphorylating Stat1 and blocking interferon (IFN)-stimulated innate immune responses. Vaccinia virus (VACV) H1 can inhibit the phosphorylation of the transcription factor Stat1 after IFN-γ stimulation of epithelial cells, greatly attenuating IFN-induced biological functions. In this study, we demonstrate that VACV infection is capable of inhibiting the phosphorylation of Stat1 and Stat2 after stimulation of fibroblasts or bone marrowderived macrophages with either type I or type II IFNs, but did not inhibit the activation of Stat3 or Stat5 in either cell type. By using recombinant proteins for in vitro assays, we observe that variola virus H1 is more active than VACV H1, although it has similar selectivity for Stat targets. Differential effects of VACV infection were observed on the induction of IFN-stimulated genes, with complete inhibition of some genes by VACV infection, while others were less affected. Despite the IFN-γ-induced expression of some genes in VACV-infected cells, IFN-γ was unable to rescue the VACV-mediated inhibition of MHC class II antigen presentation. Moreover, VACV infection can affect the IFN-induced expression of Stat1-dependent and Stat1-independent genes, suggesting that the virus may target additional IFN-activated pathways. Thus, VACV targets multiple signaling pathways in the evasion of antiviral immune responses.
Interleukin 1 is a pleiotropic cytokine produced from macrophages and dendritic cells, which induces several responses in T cells including increased proliferation, increased cytotoxic activity, and Th1 differentiation (1). IL-12 activates several signaling pathways that may mediate these biological activities including p38 MAPK and the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway (2-5). Upon binding of IL-12, both chains of the IL-12 receptor (IL-12R1 and IL-12R2) heterodimerize and activate the associated JAKs, TYK2, and JAK2. The IL-12R2 chain is subsequently tyrosine phosphorylated and recruits STAT4 to a specific docking site where it is itself phosphorylated (6). The phosphorylated STAT4 monomers then homodimerize and translocate into the nucleus. STAT4 is required for many of the functions of IL-12 including the induction of IFN-␥ and the differentiation of Th1 cells (7,8).Once in the nucleus, STAT4 binds to a cognate binding sequence within IL-12 responsive genes to subsequently mediate activation of transcription (9 -11). Several IL-12 responsive genes that require STAT4 for transcriptional activation have been identified including IFN-␥ (7-9, 12), IL-18R␣ (13, 14), ERM (15) and IRF-1 (10, 11). STAT4 may interact with other transcription factors at a promoter through several domains, including the C-terminal "transactivation domain." However, both STAT4 isoforms, STAT4␣ and STAT4 (16), the latter of which lacks the C-terminal 40 amino acids encompassing the putative transcription activation domain, are able to activate transcription and mediate many IL-12 responses. This suggests that interactions of other transcription factors with the STAT4 transactivation domain are not required for all STAT4-dependent responses. Furthermore, the events that STAT4 initiates at a promoter, and the kinetics with which they occur have not been characterized.CD25 is the ␣ chain of the high affinity IL-2 receptor complex. CD25 is only expressed upon T cell activation, and expression is further modulated by IL-2 stimulation. Transcription of CD25 is regulated by multiple transcription factors that bind to elements termed positive regulatory regions (PRR) in the CD25 promoter and intronic regions. PRRI is located around 260 nucleotides upstream of the major transcription initiation sites in the mouse gene (Ϫ276 to Ϫ244 in human) (17-19) and binds NF-B and serum response factor (20). PR-RII is around Ϫ100 in the mouse gene (Ϫ137 to Ϫ64 in human) and binds . PRRIII, also known as the IL-2 responsive element (IL-2rE), is located Ϫ1306 to Ϫ1387 in the mouse gene (Ϫ3780 to Ϫ3703 in human), and one of the tandem STAT5 binding sites overlaps a binding site for . In the mouse gene, an additional regulatory element at Ϫ576 to Ϫ667 that contains binding sites for NFAT and AP-1 proteins is also required for T cell receptor-mediated induction of IL-2R␣ chain expression (27). Recently, two additional elements in the human gene have been identified, a CD28 responsive element (CD28rE) at Ϫ8.5 kB t...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.